US2016289281A1PendingUtilityA1

Peptide with multiple epitopes

59
Assignee: CIRCASSIA LTDPriority: Aug 15, 2007Filed: Apr 11, 2016Published: Oct 6, 2016
Est. expiryAug 15, 2027(~1.1 yrs left)· nominal 20-yr term from priority
Inventors:Roderick Peter HafnerMark Larche
A61P 7/06A61P 33/14A61P 37/02A61P 3/10A61P 37/08A61P 37/06A61P 11/02A61P 11/06A61P 19/02A61P 17/00A61K 39/0002C07K 14/435A61K 38/17C07K 2319/00C07K 14/415A61K 39/35A61K 39/0003A61K 39/39C07K 14/43531A61K 39/0005C07K 7/08C07K 16/16C07K 16/18G01N 33/56977A61K 39/36A61K 39/0008C07K 7/06A61K 38/00
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to peptides comprising multiple MHC Class II-binding T cell epitopes for tolerisation therapy.

Claims

exact text as granted — not AI-modified
1 . (canceled) 
     
     
         2 . A composition comprising a peptide which has a length of 10 to 25 amino acids and which comprises a region having the sequence of SEQ ID NO: 60 or SEQ ID NO: 81. 
     
     
         3 . A composition according to  claim 2  which additionally comprises a pharmaceutically acceptable carrier and an adjuvant. 
     
     
         4 . A composition according to  claim 2  which additionally comprises an effective amount of a preservative and a pharmaceutically acceptable carrier.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.